A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg

Cheol Whan Lee, Sang Hong Baek, Taek Jong Hong, Young Jin Choi, Young Jo Kim, Tae Hoon Ahn, Sang Hyun Ihm, Jang Ho Bae, Soon Jun Hong, Doo Il Kim, Young Keun Ahn, Seung Ho Hur, Dae Gyun Park, Dong Ju Choi, Seung Uk Lee, Bum Soo Kim, Kyu Hyung Ryu, Yang Soo Jang, Sang Hoon Lee, Ki Bae Seung & 1 others Hyo Soo Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: This study was designed to evaluate the safety and efficacy of algorithm-based atorvastatin therapy initiated at different starting doses of 10, 20, and 40 mg in Korean dyslipidemic patients. Methods: Five hundred seventy-four patients were screened, and 425 were enrolled (low risk, n=29; intermediate risk, n=45; high risk, n=351). The starting dose depended on a patient's cardiovascular risk and LDL-cholesterol (LDL-C) levels. Results: Of the patients, 253 (59.5%), 63 (14.8%) and 109 (25.6%) patients were assigned at baseline to 10 mg, 20 mg and 40 mg atorvastatin, respectively. 390 patients (91.8%) completed the study, and 35 discontinued prematurely. No patient in the low or intermediate risk groups was titrated to 80 mg at Week 4, whereas, 26 in the high risk group were. 81.9% of patients achieved their LDL-C target at Week 4, which was sustained through to Week 8 (86.0%). 89.1% of patients who were not titrated achieved their LDL-C target at Week 8, and 82.1% of patients who were titrated 1 step up achieved their LDL-C target at Week 8. Overall, about 40% reduction in LDL-C, non-HDL-C levels, and LDL-C/HDL-C ratio was observed during the follow-up. Triglyceride was reduced by ∼10% by Week 8. HDL cholesterol was slightly increased over 8 weeks (2.6%). Atorvastatin was well tolerated at all dose levels. Conclusions: Patient-tailored statin therapy according to an individual's risk category and LDL-C levels was safe and effective with a quick achievement of LDL-C target in Korean dyslipidemic patients.

Original languageEnglish
Pages (from-to)181-188
Number of pages8
JournalCardiovascular Drugs and Therapy
Volume24
Issue number2
DOIs
Publication statusPublished - 2010 Apr 1

Fingerprint

LDL Cholesterol
Therapeutics
Atorvastatin Calcium
Hydroxymethylglutaryl-CoA Reductase Inhibitors
HDL Cholesterol
Triglycerides
Safety

Keywords

  • Atorvastatin
  • Dyslipidemia
  • Flexible-starting dose
  • Target goal achievement

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg. / Lee, Cheol Whan; Baek, Sang Hong; Hong, Taek Jong; Choi, Young Jin; Kim, Young Jo; Ahn, Tae Hoon; Ihm, Sang Hyun; Bae, Jang Ho; Hong, Soon Jun; Kim, Doo Il; Ahn, Young Keun; Hur, Seung Ho; Park, Dae Gyun; Choi, Dong Ju; Lee, Seung Uk; Kim, Bum Soo; Ryu, Kyu Hyung; Jang, Yang Soo; Lee, Sang Hoon; Seung, Ki Bae; Kim, Hyo Soo.

In: Cardiovascular Drugs and Therapy, Vol. 24, No. 2, 01.04.2010, p. 181-188.

Research output: Contribution to journalArticle

Lee, CW, Baek, SH, Hong, TJ, Choi, YJ, Kim, YJ, Ahn, TH, Ihm, SH, Bae, JH, Hong, SJ, Kim, DI, Ahn, YK, Hur, SH, Park, DG, Choi, DJ, Lee, SU, Kim, BS, Ryu, KH, Jang, YS, Lee, SH, Seung, KB & Kim, HS 2010, 'A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg', Cardiovascular Drugs and Therapy, vol. 24, no. 2, pp. 181-188. https://doi.org/10.1007/s10557-010-6225-0
Lee, Cheol Whan ; Baek, Sang Hong ; Hong, Taek Jong ; Choi, Young Jin ; Kim, Young Jo ; Ahn, Tae Hoon ; Ihm, Sang Hyun ; Bae, Jang Ho ; Hong, Soon Jun ; Kim, Doo Il ; Ahn, Young Keun ; Hur, Seung Ho ; Park, Dae Gyun ; Choi, Dong Ju ; Lee, Seung Uk ; Kim, Bum Soo ; Ryu, Kyu Hyung ; Jang, Yang Soo ; Lee, Sang Hoon ; Seung, Ki Bae ; Kim, Hyo Soo. / A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg. In: Cardiovascular Drugs and Therapy. 2010 ; Vol. 24, No. 2. pp. 181-188.
@article{0bbe8d25a8aa4b8298f747615710b49a,
title = "A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg",
abstract = "Background: This study was designed to evaluate the safety and efficacy of algorithm-based atorvastatin therapy initiated at different starting doses of 10, 20, and 40 mg in Korean dyslipidemic patients. Methods: Five hundred seventy-four patients were screened, and 425 were enrolled (low risk, n=29; intermediate risk, n=45; high risk, n=351). The starting dose depended on a patient's cardiovascular risk and LDL-cholesterol (LDL-C) levels. Results: Of the patients, 253 (59.5{\%}), 63 (14.8{\%}) and 109 (25.6{\%}) patients were assigned at baseline to 10 mg, 20 mg and 40 mg atorvastatin, respectively. 390 patients (91.8{\%}) completed the study, and 35 discontinued prematurely. No patient in the low or intermediate risk groups was titrated to 80 mg at Week 4, whereas, 26 in the high risk group were. 81.9{\%} of patients achieved their LDL-C target at Week 4, which was sustained through to Week 8 (86.0{\%}). 89.1{\%} of patients who were not titrated achieved their LDL-C target at Week 8, and 82.1{\%} of patients who were titrated 1 step up achieved their LDL-C target at Week 8. Overall, about 40{\%} reduction in LDL-C, non-HDL-C levels, and LDL-C/HDL-C ratio was observed during the follow-up. Triglyceride was reduced by ∼10{\%} by Week 8. HDL cholesterol was slightly increased over 8 weeks (2.6{\%}). Atorvastatin was well tolerated at all dose levels. Conclusions: Patient-tailored statin therapy according to an individual's risk category and LDL-C levels was safe and effective with a quick achievement of LDL-C target in Korean dyslipidemic patients.",
keywords = "Atorvastatin, Dyslipidemia, Flexible-starting dose, Target goal achievement",
author = "Lee, {Cheol Whan} and Baek, {Sang Hong} and Hong, {Taek Jong} and Choi, {Young Jin} and Kim, {Young Jo} and Ahn, {Tae Hoon} and Ihm, {Sang Hyun} and Bae, {Jang Ho} and Hong, {Soon Jun} and Kim, {Doo Il} and Ahn, {Young Keun} and Hur, {Seung Ho} and Park, {Dae Gyun} and Choi, {Dong Ju} and Lee, {Seung Uk} and Kim, {Bum Soo} and Ryu, {Kyu Hyung} and Jang, {Yang Soo} and Lee, {Sang Hoon} and Seung, {Ki Bae} and Kim, {Hyo Soo}",
year = "2010",
month = "4",
day = "1",
doi = "10.1007/s10557-010-6225-0",
language = "English",
volume = "24",
pages = "181--188",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg

AU - Lee, Cheol Whan

AU - Baek, Sang Hong

AU - Hong, Taek Jong

AU - Choi, Young Jin

AU - Kim, Young Jo

AU - Ahn, Tae Hoon

AU - Ihm, Sang Hyun

AU - Bae, Jang Ho

AU - Hong, Soon Jun

AU - Kim, Doo Il

AU - Ahn, Young Keun

AU - Hur, Seung Ho

AU - Park, Dae Gyun

AU - Choi, Dong Ju

AU - Lee, Seung Uk

AU - Kim, Bum Soo

AU - Ryu, Kyu Hyung

AU - Jang, Yang Soo

AU - Lee, Sang Hoon

AU - Seung, Ki Bae

AU - Kim, Hyo Soo

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Background: This study was designed to evaluate the safety and efficacy of algorithm-based atorvastatin therapy initiated at different starting doses of 10, 20, and 40 mg in Korean dyslipidemic patients. Methods: Five hundred seventy-four patients were screened, and 425 were enrolled (low risk, n=29; intermediate risk, n=45; high risk, n=351). The starting dose depended on a patient's cardiovascular risk and LDL-cholesterol (LDL-C) levels. Results: Of the patients, 253 (59.5%), 63 (14.8%) and 109 (25.6%) patients were assigned at baseline to 10 mg, 20 mg and 40 mg atorvastatin, respectively. 390 patients (91.8%) completed the study, and 35 discontinued prematurely. No patient in the low or intermediate risk groups was titrated to 80 mg at Week 4, whereas, 26 in the high risk group were. 81.9% of patients achieved their LDL-C target at Week 4, which was sustained through to Week 8 (86.0%). 89.1% of patients who were not titrated achieved their LDL-C target at Week 8, and 82.1% of patients who were titrated 1 step up achieved their LDL-C target at Week 8. Overall, about 40% reduction in LDL-C, non-HDL-C levels, and LDL-C/HDL-C ratio was observed during the follow-up. Triglyceride was reduced by ∼10% by Week 8. HDL cholesterol was slightly increased over 8 weeks (2.6%). Atorvastatin was well tolerated at all dose levels. Conclusions: Patient-tailored statin therapy according to an individual's risk category and LDL-C levels was safe and effective with a quick achievement of LDL-C target in Korean dyslipidemic patients.

AB - Background: This study was designed to evaluate the safety and efficacy of algorithm-based atorvastatin therapy initiated at different starting doses of 10, 20, and 40 mg in Korean dyslipidemic patients. Methods: Five hundred seventy-four patients were screened, and 425 were enrolled (low risk, n=29; intermediate risk, n=45; high risk, n=351). The starting dose depended on a patient's cardiovascular risk and LDL-cholesterol (LDL-C) levels. Results: Of the patients, 253 (59.5%), 63 (14.8%) and 109 (25.6%) patients were assigned at baseline to 10 mg, 20 mg and 40 mg atorvastatin, respectively. 390 patients (91.8%) completed the study, and 35 discontinued prematurely. No patient in the low or intermediate risk groups was titrated to 80 mg at Week 4, whereas, 26 in the high risk group were. 81.9% of patients achieved their LDL-C target at Week 4, which was sustained through to Week 8 (86.0%). 89.1% of patients who were not titrated achieved their LDL-C target at Week 8, and 82.1% of patients who were titrated 1 step up achieved their LDL-C target at Week 8. Overall, about 40% reduction in LDL-C, non-HDL-C levels, and LDL-C/HDL-C ratio was observed during the follow-up. Triglyceride was reduced by ∼10% by Week 8. HDL cholesterol was slightly increased over 8 weeks (2.6%). Atorvastatin was well tolerated at all dose levels. Conclusions: Patient-tailored statin therapy according to an individual's risk category and LDL-C levels was safe and effective with a quick achievement of LDL-C target in Korean dyslipidemic patients.

KW - Atorvastatin

KW - Dyslipidemia

KW - Flexible-starting dose

KW - Target goal achievement

UR - http://www.scopus.com/inward/record.url?scp=77955417265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955417265&partnerID=8YFLogxK

U2 - 10.1007/s10557-010-6225-0

DO - 10.1007/s10557-010-6225-0

M3 - Article

VL - 24

SP - 181

EP - 188

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 2

ER -